Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles ...

We view Avita’s RECELL system as a sound alternative treatment for large second- and third-degree burns treated in burn centers. It compares favorably on price and ease of use with new products and ...

A new report from industry trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has shed a new light ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...

Healthcare technology startup, Weave Cloud Solutions, has secured private funding to launch a generative AI (GenAI) and intelligent document processing (IDP) solution that streamlines administrative ...

In statements and interviews with The Crimson, nine life sciences researchers at Harvard — from the Harvard School of Public ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

A nutritional scientist has spoken about a ‘superfood’ which costs 30p each which can reducing inflammation and lowering ...